cdx-301
cdx-301: 4 clinical trials tracked.
cdx-301 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about cdx-301, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (4)
Phase 1 Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic HER2 Negative Breast Cancer
Primary endpoint: Safety (tolerability) of the drug combination of CDX-1140, CDX-301 and PLD as measured by the number of participants with Dose Limiting Toxicity (DLT)
A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma
Primary endpoint: Rate of Dose Limiting Toxicity (DLT)
Converting HR+ Breast Cancer Into an Individualized Vaccine
Primary endpoint: Tolerability will be demonstrated if no grade 3 or higher toxicities are observed in the first 8 patients, of each arm.
In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma
Primary endpoint: Dose Limiting Toxicity (DLT)